FB Nasdaq FB Facebook

Biotech Gainers: Novavax (NASDAQ:NVAX), OXiGENE Inc (NASDAQ:OXGN), Imprimis Pharmaceuticals (NASDAQ:IMMY), Oramed Pharmaceuticals (NASDAQ:ORMP)

Novavax (NASDAQ:NVAX) Director Richard Douglas acquired 50,000 shares of Novavax stock in a transaction that occurred on Tuesday, March 25th. Novavax, Inc. (NASDAQ:NVAX) stock performance was 8.47% in last session and finished the day at $4.48. Traded volume was 7,425,052 million shares in the last session and the average volume of the stock remained 5.05 million shares. The beta of the stock remained 2.15. Novavax, … Continue reading Biotech Gainers: Novavax (NASDAQ:NVAX), OXiGENE Inc (NASDAQ:OXGN), Imprimis Pharmaceuticals (NASDAQ:IMMY), Oramed Pharmaceuticals (NASDAQ:ORMP)

Healthcare Most Volatile: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), OXiGENE Inc (NASDAQ:OXGN), Intrexon (NYSE:XON), Enzon Pharmaceuticals (NASDAQ:ENZN)

Idenix Pharmaceuticals (NASDAQ:IDIX) , which had its hepatitis C drugs put on clinical hold because it had a similar structure to Bristol-Myers Squibb’s BMS-986094, which had serious cardiac side effects. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was -6.45% in last session and finished the day at $7.11. Traded volume was 3,306,727 million shares in the last session and the average volume of the stock remained … Continue reading Healthcare Most Volatile: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), OXiGENE Inc (NASDAQ:OXGN), Intrexon (NYSE:XON), Enzon Pharmaceuticals (NASDAQ:ENZN)

Biotech Losers: Geron Corporation (NASDAQ:GERN), OXiGENE Inc (NASDAQ:OXGN), Opexa Therapeutics Inc (NASDAQ:OPXA), 22nd Century Group Inc (NYSEMKT:XXII)

Brower Piven, A Professional Corporation on Mar. 18 announced that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was -8.06% in last session and finished … Continue reading Biotech Losers: Geron Corporation (NASDAQ:GERN), OXiGENE Inc (NASDAQ:OXGN), Opexa Therapeutics Inc (NASDAQ:OPXA), 22nd Century Group Inc (NYSEMKT:XXII)

Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and … Continue reading Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Biotech Unusual Volume: OXiGENE Inc (NASDAQ:OXGN), TESARO Inc (NASDAQ:TSRO), Discovery Laboratories (NASDAQ:DSCO), Albany Molecular Research (NASDAQ:AMRI)

OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared … Continue reading Biotech Unusual Volume: OXiGENE Inc (NASDAQ:OXGN), TESARO Inc (NASDAQ:TSRO), Discovery Laboratories (NASDAQ:DSCO), Albany Molecular Research (NASDAQ:AMRI)